Topic: coronary artery disease
HDL unveiled data showing its treatment reduced reduced coronary artery damage in patients with a genetic disorder that causes high cholesterol.
Medtronic showed that its Resolute Onyx drug-eluting stent showed success in patients at high risk for bleeding, who are often excluded from studies.
The FDA approved Bayer’s Gadavist MRI contrast agent to help gauge the blood supply of the heart muscle.
Hot on the heels of an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices.
Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.
The first new option in 17 years, Biotronik’s sheathed emergency stent is used to seal off perforations in the blood vessels of the heart.
Verve Therapeutics is launching with $58.5 million access to CRISPR and base-editing tech and cardiologist and geneticist Sekar Kathiresan as CEO.
The drug-eluting balloon opens up the coronary arteries after they’ve reclogged without using a traditional drug coating.
2015 Fierce 15 company Shockwave Medical is going public, filing for a $75 million IPO on the Nasdaq with the ticker symbol SWAV.
The primary endpoint successes in patients with stable CAD or AMI set Idorsia up to plan the initiation of a phase 3 study.